Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 18 studies | 37% ± 12% | |
peripheral blood | 17 studies | 35% ± 12% | |
brain | 10 studies | 27% ± 10% | |
kidney | 8 studies | 30% ± 9% | |
intestine | 7 studies | 24% ± 5% | |
liver | 6 studies | 36% ± 12% | |
heart | 5 studies | 47% ± 16% | |
uterus | 5 studies | 26% ± 11% | |
breast | 5 studies | 23% ± 4% | |
lymph node | 4 studies | 29% ± 9% | |
prostate | 4 studies | 35% ± 7% | |
adipose | 4 studies | 39% ± 8% | |
bone marrow | 3 studies | 30% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 18928.66 | 1445 / 1445 | 100% | 17.46 | 183 / 183 |
intestine | 100% | 16580.94 | 966 / 966 | 100% | 12.54 | 527 / 527 |
prostate | 100% | 17475.02 | 245 / 245 | 100% | 14.33 | 502 / 502 |
thymus | 100% | 20966.28 | 653 / 653 | 100% | 22.27 | 604 / 605 |
lung | 100% | 29962.72 | 578 / 578 | 100% | 19.15 | 1153 / 1155 |
kidney | 100% | 12246.31 | 89 / 89 | 99% | 24.82 | 896 / 901 |
stomach | 99% | 10346.86 | 357 / 359 | 100% | 14.27 | 285 / 286 |
uterus | 100% | 15436.71 | 170 / 170 | 99% | 12.00 | 454 / 459 |
breast | 100% | 16788.11 | 459 / 459 | 99% | 13.49 | 1105 / 1118 |
liver | 100% | 6726.70 | 225 / 226 | 99% | 9.61 | 403 / 406 |
bladder | 100% | 15798.19 | 21 / 21 | 99% | 11.61 | 498 / 504 |
ovary | 99% | 8894.37 | 179 / 180 | 99% | 10.52 | 425 / 430 |
skin | 100% | 10319.81 | 1800 / 1809 | 93% | 8.94 | 440 / 472 |
adrenal gland | 100% | 10420.07 | 258 / 258 | 93% | 7.48 | 213 / 230 |
pancreas | 94% | 5678.87 | 307 / 328 | 99% | 18.99 | 176 / 178 |
brain | 71% | 5533.55 | 1877 / 2642 | 99% | 8.34 | 700 / 705 |
adipose | 100% | 19228.15 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 31.73 | 29 / 29 |
muscle | 100% | 26560.57 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 22435.19 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 15.96 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.12 | 1 / 1 |
blood vessel | 100% | 13082.34 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 22726.14 | 860 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 27318.38 | 918 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 83% | 5.75 | 66 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0014732 | Biological process | skeletal muscle atrophy |
GO_0033574 | Biological process | response to testosterone |
GO_0030216 | Biological process | keratinocyte differentiation |
GO_0097190 | Biological process | apoptotic signaling pathway |
GO_0072126 | Biological process | positive regulation of glomerular mesangial cell proliferation |
GO_2000347 | Biological process | positive regulation of hepatocyte proliferation |
GO_0007519 | Biological process | skeletal muscle tissue development |
GO_0071549 | Biological process | cellular response to dexamethasone stimulus |
GO_0032869 | Biological process | cellular response to insulin stimulus |
GO_0010976 | Biological process | positive regulation of neuron projection development |
GO_0071364 | Biological process | cellular response to epidermal growth factor stimulus |
GO_0060544 | Biological process | regulation of necroptotic process |
GO_1903845 | Biological process | negative regulation of cellular response to transforming growth factor beta stimulus |
GO_0071392 | Biological process | cellular response to estradiol stimulus |
GO_0043403 | Biological process | skeletal muscle tissue regeneration |
GO_0071732 | Biological process | cellular response to nitric oxide |
GO_1903944 | Biological process | negative regulation of hepatocyte apoptotic process |
GO_0043525 | Biological process | positive regulation of neuron apoptotic process |
GO_1903427 | Biological process | negative regulation of reactive oxygen species biosynthetic process |
GO_0042060 | Biological process | wound healing |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0030218 | Biological process | erythrocyte differentiation |
GO_0030182 | Biological process | neuron differentiation |
GO_1903055 | Biological process | positive regulation of extracellular matrix organization |
GO_0014866 | Biological process | skeletal myofibril assembly |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0014842 | Biological process | regulation of skeletal muscle satellite cell proliferation |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_1901740 | Biological process | negative regulation of myoblast fusion |
GO_0006508 | Biological process | proteolysis |
GO_2001237 | Biological process | negative regulation of extrinsic apoptotic signaling pathway |
GO_0097194 | Biological process | execution phase of apoptosis |
GO_0006915 | Biological process | apoptotic process |
GO_1902042 | Biological process | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors |
GO_0010667 | Biological process | negative regulation of cardiac muscle cell apoptotic process |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0071456 | Biological process | cellular response to hypoxia |
GO_0097342 | Cellular component | ripoptosome |
GO_0031265 | Cellular component | CD95 death-inducing signaling complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0031264 | Cellular component | death-inducing signaling complex |
GO_0008047 | Molecular function | enzyme activator activity |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_0002020 | Molecular function | protease binding |
GO_0097200 | Molecular function | cysteine-type endopeptidase activity involved in execution phase of apoptosis |
GO_0097199 | Molecular function | cysteine-type endopeptidase activity involved in apoptotic signaling pathway |
GO_0005123 | Molecular function | death receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CFLAR |
Protein name | CASP8 and FADD-like apoptosis regulator (Caspase homolog) (CASH) (Caspase-eight-related protein) (Casper) (Caspase-like apoptosis regulatory protein) (CLARP) (Cellular FLICE-like inhibitory protein) (c-FLIP) (FADD-like antiapoptotic molecule 1) (FLAME-1) (Inhibitor of FLICE) (I-FLICE) (MACH-related inducer of toxicity) (MRIT) (Usurpin) [Cleaved into: CASP8 and FADD-like apoptosis regulator subunit p43; CASP8 and FADD-like apoptosis regulator subunit p12] CASP8 and FADD like apoptosis regulator CASP8 and FADD-like apoptosis regulator, isoform CRA_a (Usurpin-beta splice variant) |
Synonyms | MRIT CASP8AP1 CASH hCG_16553 CLARP |
Description | FUNCTION: Apoptosis regulator protein which may function as a crucial link between cell survival and cell death pathways in mammalian cells. Acts as an inhibitor of TNFRSF6 mediated apoptosis. A proteolytic fragment (p43) is likely retained in the death-inducing signaling complex (DISC) thereby blocking further recruitment and processing of caspase-8 at the complex. Full length and shorter isoforms have been shown either to induce apoptosis or to reduce TNFRSF-triggered apoptosis. Lacks enzymatic (caspase) activity. . |
Accessions | ENST00000341222.10 [O15519-2] ENST00000470178.6 ENST00000457277.5 [O15519-11] ENST00000395148.6 C9J408 O15519 ENST00000423241.6 [O15519-1] C9J4Q0 M0QYM0 A0A336TY74 ENST00000494258.5 ENST00000342795.9 [O15519-12] F8WBH9 ENST00000439154.6 ENST00000433445.1 C9JSU3 ENST00000417748.1 M0R1A8 ENST00000479953.6 [O15519-3] E9PAP3 ENST00000441224.5 ENST00000341582.10 [O15519-8] ENST00000309955.8 [O15519-1] ENST00000425030.1 ENST00000440180.5 [O15519-2] ENST00000462763.5 ENST00000443227.5 [O15519-15] C9JV51 M0QY57 |